Medicaid rebates 1991
Executive Summary
Glaxo reports paying Medicaid rebates of $60 mil. during second half of calendar 1991. If the company's payments in the first six months were at a similar level, it may well have rebated over $100 mil. to the state and federal governments in 1991. The total rebates for 1991 have been estimated in the $570 mil. range. Glaxo may be paying around 20% of the rebates. By comparison, Bristol-Myers Squibb paid rebates of $55 mil. in 1991; Pfizer $44 mil., Merck approximately $30-$35 mil.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth